Literature DB >> 9096605

Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats.

T Grøfte1, T Wolthers, S A Jensen, N Møller, J O Jørgensen, N Tygstrup, H Orskov, H Vilstrup.   

Abstract

Improvement of nitrogen balance is desirable in patients with acute or chronic illness. Both growth hormone (GH) and insulin-like growth factor-I (IGF-I) are promising anabolic agents, and their combined administration has been shown to reverse catabolism more efficiently than each of the peptides alone. This is believed to be mediated primarily through increased peripheral protein synthesis, whereas little attention has focused on a possible participation of amino acid metabolism in the liver. Four groups of rats were given: 1) placebo; 2) GH (200 micrograms/d); 3) IGF-I (300 micrograms/d); and 4) both GH and IGF-I. After 3 days, the maximum capacity of urea-nitrogen synthesis was determined by saturating infusion of alanine (n = 8 in each group), together with measurements of liver messenger RNA (mRNA) levels for urea cycle enzymes (n = 5 in each group) and N-contents of muscles, heart, and kidney. Basal plasma alpha-amino acid concentrations were similar in all groups. The capacity of urea-N synthesis [mumol/(min x 100 g body weight)] was reduced in a stepwise manner (placebo: 8.25 +/- 1.2; GH treatment: 6.52 +/- 0.8; IGF-I treatment: 5.5 +/- 0.6; and GH/IGF-I: 4.22 +/- 1.6 [P < .001 by ANOVA]), each step being lower than the former. Serum IGF-I increased stepwise from placebo (699 +/- 40 to 1,579 +/- 96 micrograms/L in the combined GH/IGF-I group), and was correlated negatively with the capacity of urea-nitrogen synthesis (P < .01). mRNA levels for urea cycle enzymes in the liver decreased after GH and IGF-I treatment, and the effect was more pronounced after the combined treatment in which the rate-limiting enzyme, argininosuccinate synthetase, was halved. Nitrogen contents of organs increased after both GH and IGF-I treatment, and even more so after the combination treatment, reaching an increase of 30% (P < .05). Data suggest that GH and IGF-I singly and, even more so in combination, additively inhibit urea synthesis. This is supposed to favor protein buildup in organs. We speculate that this inhibitory effect on the capacity of urea synthesis is caused by a decreased translation rate of the urea cycle enzymes caused by GH and IGF-I's down-regulatory effect on urea cycle enzyme gene transcription. The findings may indicate a novel mechanism of the protein anabolic action of GH and IGF-I.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096605     DOI: 10.1002/hep.510250429

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Could quantitative liver function tests gain wide acceptance among hepatologists?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

2.  Glucocorticoids affect metabolic but not muscle microvascular insulin sensitivity following high versus low salt intake.

Authors:  Monica Tj Schütten; Yvo Ham Kusters; Alfons Jhm Houben; Hanneke E Niessen; Jos Op 't Roodt; Jean Ljm Scheijen; Marjo P van de Waardenburg; Casper G Schalkwijk; Peter W de Leeuw; Coen DA Stehouwer
Journal:  JCI Insight       Date:  2020-03-26

Review 3.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

4.  Recombinant human growth hormone (rhGH) treatment of MKN-45 xenograft mice improves nutrition status and strengthens immune function without promoting tumor growth.

Authors:  Lianping Wei; Jianrong Chang; Zhen Han; Ronghai Wang; Lihua Song
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

5.  A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy.

Authors:  Teresa Lam; Mark McLean; Amy Hayden; Anne Poljak; Birinder Cheema; Howard Gurney; Glenn Stone; Neha Bahl; Navneeta Reddy; Haleh Shahidipour; Vita Birzniece
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

6.  Recombinant Human Growth Hormone Inhibits Lipotoxicity, Oxidative Stress, and Apoptosis in a Mouse Model of Diabetic Cardiomyopathy.

Authors:  Zuowei Pei; Xiang Wang; Chenguang Yang; Min Dong; Fang Wang
Journal:  Oxid Med Cell Longev       Date:  2021-12-09       Impact factor: 6.543

Review 7.  Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.

Authors:  Mabrouka A Altowati; Richard K Russell; S Faisal Ahmed
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

8.  Lipid profiling and transcriptomic analysis reveals a functional interplay between estradiol and growth hormone in liver.

Authors:  Leandro Fernández-Pérez; Ruymán Santana-Farré; Mercedes de Mirecki-Garrido; Irma García; Borja Guerra; Carlos Mateo-Díaz; Diego Iglesias-Gato; Juan Carlos Díaz-Chico; Amilcar Flores-Morales; Mario Díaz
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.